381 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Buy
Article Searches
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. http://www.zacks.com/stock/news/188907/novartis-nvs-launches-zarxio-first-biosimilar-in-the-us?cid=CS-ZC-FT-188907 Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Bristol-Myers/AbbVie Cancer Drug Gets Priority Review http://www.zacks.com/stock/news/188749/bristol-myers-abbvie-cancer-drug-gets-priority-review?cid=CS-ZC-FT-188749 Sep 02, 2015 - Bristol-Myers Squibb Company (BMY) and its partner AbbVie (ABBV) announced that the BLA for Empliciti has been accepted with priority review by the FDA.
Perrigo (PRGO) Buys Scar Management Brand from Enaltus http://www.zacks.com/stock/news/188561/perrigo-prgo-buys-scar-management-brand-from-enaltus?cid=CS-ZC-FT-188561 Sep 01, 2015 - Perrigo Company plc (PRGO) announced that it has acquired a leading U.S. OTC scar management brand, ScarAway, from Enaltus.
ESC - Case Builds For Jardiance http://seekingalpha.com/article/3481466-esc-case-builds-for-jardiance?source=feed_sector_healthcare Sep 01, 2015 -
ITCA-650 Poised For Leadership In Type 2 Diabetes: Implications For Merck And Novo Nordisk http://seekingalpha.com/article/3477866-itcaminus-650-poised-for-leadership-in-type-2-diabetes-implications-for-merck-and-novo-nordisk?source=feed_sector_healthcare Sep 01, 2015 - ITCA-650 should reach the market in 2017 and has the potential to change competitive dynamics in type 2 diabetes space.
After Hours Gainers / Losers http://seekingalpha.com/news/2754326-after-hours-gainers-losers?source=feed_news_all Aug 31, 2015 - Top gainers, as of 5.25 p.m.: [[TRVN]] +41.0%. [[DBVT]] +4.4%. [[SUNE]] +4.2%. [[JAKK]] +2.4%. [[NVO]] +1.1%. Top losers, as of 5.25p.m.: [[ACI]] -8.7%. [[
Bristol-Myers Inks Another Immuno-Oncology Drug Deal http://www.zacks.com/stock/news/188393/bristol-myers-inks-another-immuno-oncology-drug-deal?cid=CS-ZC-FT-188393 Aug 31, 2015 - Bristol-Myers Squibb Company (BMY) announced that it has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute.
Is Novo Nordisk (NVO) an Incredible Growth Stock? 3 Reasons Why It Will Be Tough to Beat http://www.zacks.com/stock/news/188252/novo-nordisk-may-be-an-impressive-growth-pick-right-now?cid=CS-ZC-FT-188252 Aug 31, 2015 - Novo Nordisk stock is a potential outperformer that is an impressive choice for growth investors, making it a security that you need to keep on your radar in the near term
Novo's Oral GLP-1 Looks Sweeter http://seekingalpha.com/article/3474406-novos-oral-glpminus-1-looks-sweeter?source=feed_sector_healthcare Aug 28, 2015 - Another day, another diabetes development. In the GLP-1 alternative delivery game Intarcia Therapeutics gained an edge last week with its ITCA 650 implant, but Novo Nordisk (NYSE:NVO) is close behind
Novo Nordisk to Start PIONEER Program on Semaglutide http://www.zacks.com/stock/news/188031/novo-nordisk-to-start-pioneer-program-on-semaglutide?cid=CS-ZC-FT-188031 Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.

Pages: 1...33343536373839

<<<Page 38